Asthma-COPD overlap: current understanding and the utility of experimental models

Asthma-COPD overlap: current understanding and the utility of experimental models.

Full text not available from this repository.
Item Type: Review
Status: Published
Official URL:
Journal or Publication Title: European Respiratory Review
Volume: 30
Number: 159
Page Range: p. 190185
Date: 2021
Divisions: UTS Centre for Inflammation
Depositing User: General Admin
Identification Number: 10.1183/16000617.0185-2019
ISSN: 0905-9180
Date Deposited: 10 Jun 2021 00:00

Pathological features of both asthma and COPD coexist in some patients and this is termed asthma-COPD overlap (ACO). ACO is heterogeneous and patients exhibit various combinations of asthma and COPD features, making it difficult to characterise the underlying pathogenic mechanisms. There are no controlled studies that define effective therapies for ACO, which arises from the lack of international consensus on the definition and diagnostic criteria for ACO, as well as scant in vitro and in vivo data. There remain unmet needs for experimental models of ACO that accurately recapitulate the hallmark features of ACO in patients. The development and interrogation of such models will identify underlying disease-causing mechanisms, as well as enabling the identification of novel therapeutic targets and providing a platform for assessing new ACO therapies. Here, we review the current understanding of the clinical features of ACO and highlight the approaches that are best suited for developing representative experimental models of ACO.

Copyright ©ERS 2021

Tu, Xiaofan
Donovan, Chantal
Kim, Richard Y.
Wark, Peter A.B.
Horvat, Jay C.
Hansbro, Philip M.
Last Modified: 10 Jun 2021 00:00

Actions (login required)

View Item View Item